Simcere Pharma announced today that the National Medical Products Administration has agreed to convert XinoNex (Xinuo Te Wei tablets/ritonavir tablets combination pack) from conditional approval to regular approval for the treatment of mild to moderate COVID-19 in adult patients, becoming the first oral antiviral drug for COVID-19 approved for marketing in China. Some market insiders believe that most of the previously approved oral drugs for COVID-19 were conditionally approved, and real-world data collection studies still need to be conducted after marketing. These drugs can only collect relevant data if sold in hospitals. Now that an oral COVID-19 drug has been converted to regular approval, it means that it can be sold in social pharmacies. (Yicai)
转为常规获批，中国首款新冠口服药可在药店销售
The first Chinese COVID-19 oral medication has been approved for retail sale in pharmacies.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.